Brielle Benyon

The Food and Drug Administration agreed to speed up the review of avasopasem to treat severe oral mucositis in patients with head and neck cancer.

Combining maveropepimut-S plus Keytruda showed promising outcomes in a small group of patients with diffuse large B-cell lymphoma, study results showed.

In honor of Valentine’s Day, we asked our audience to share some love for someone who helped them through their cancer experience. Here’s what they had to say.

From education to second opinions, an expert offers tips to patients with cancer on self-advocacy, especially when it comes to fertility preservation.

Surgery is the “gold standard” of treating skin cancer, but disease type and patient preferences could determine which type of procedure is used, an expert said.

From a cancer survivor who will attend the Super Bowl thanks to the Make-a-Wish foundation to the death of a former professional bodybuilder from the disease, here’s what is happening in the oncology space this week.

After promising phase 1 results, ART0380 will be studied in a randomized phase 2 trial for patients with platinum-resistant ovarian cancer.

The FDA granted a regular approval to patients with recurrent or advanced dMMR endometrial cancer.

Survivors of childhood cancer tended to have a higher rate of clonal hematopoiesis than those without a cancer history, research showed.

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

When children with cancer received dexrazoxane alongside their chemotherapy, they tended to have fewer heart complications in the short and long term.

The Food and Drug Administration granted an investigational new drug application and green lit the continued study of GC012F for the treatment of patients with relapsed/refractory myeloma.

In honor of World Cancer Day, we asked our readers what they do to raise funds and awareness since being diagnosed.

Findings from the phase 3 NRG-GY018 trial found that the addition of Keytruda to standard chemotherapy improved progression-free survival in patients with stage 3 to 4 or recurrent endometrial cancer.

From funding updates on the Cancer Moonshot to Howie Rose’s bladder cancer diagnosis and more, here’s what’s happening in the oncology space this week.

The Food and Drug Administration approved Trodelvy for patients with pretreated, unresectable HR-positive, HER2-negative metastatic breast cancer.

Patients with breast cancer who lived in Southern states with Medicaid expansion were less likely to be diagnosed with metastatic disease and more likely to receive treatment.

In this episode of the “Cancer Horizons” podcast, “Rabbi G” discusses his global travels to teach breathwork to children with cancer, and gives an exercise listeners can use to decrease their pain and anxiety.

The first patient was dosed with lerapolturev in a phase 1/2 clinical trial evaluating the drug in patients with bladder cancer and other solid tumors.

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

Two experts explain what patients need to know about the recent approval of Brukinsa for patients with chronic lymphocytic leukemia and small lymphocytic leukemia.

We asked our audience of cancer survivors how their diagnosis affected their careers. Here’s what they had to say.

The Food and Drug Administration approved Jaypirca for patients with relapsed/refractory mantle cell lymphoma who have been previously treated with multiple lines of therapy.

From Michael Bublé opening up about his son’s cancer diagnosis to the death of “Enkyboys” social media star, here’s what’s happening in the oncology space this week.

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer.

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.

Opdivo — even when given in a low dose — was shown to improve outcomes in patients with advanced head and neck squamous cell carcinoma, highlighting a new option for patients who cannot receive the full dose.

Patients with pancreatic cancer who underwent stereotactic body radiation tended to have fewer side effects and treatment sessions compared to those who had intensity-modulated radiation therapy.

A phase 2 study will investigate the efficacy of darovasertib for patients with uveal melanoma and whether the drug can potentially result in lower radiation doses or fewer eye removal surgeries.